本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 医药行业过去几年在政策调整、泡沫出清与资本退潮中深度调整，终于在今年迎来了触底反弹，年内涨幅遥遥领先。截至8月1日，医药生物以 37.42%的涨幅(按算术平均统计)，位居板块涨幅第一，市场关注度明显提升。 值得关注的是，国内百亿私募和谐汇一 投资经理施跃管理的"和谐汇一医疗创新B类份额"成立于2022年8月16日，当时正值医药行业下行中段， 截至2025年8月1日，该产品成立以来逆市实现 ***% 的收益，成立以来年化 ***% ； 同时今年 以 来 实现了 ***% 的收益。（ 点此查看收益 ） [应监管要求，私募产品不能公开展示业绩，文中涉及收益数据用***替代，合格投资者可扫码查看收益数据。] | 排 名 | 产品简称 | 公司简称 | 意金经理 | 成本7 目 期 | 产品规模 1-7月收益 | | --- | --- | --- | --- | --- | --- | | | 和谐汇一 | 医疗创新B类 和谐汇一资产 份额 | | | (万元) | | | से हीं। | | 施跃 | 2022/8/16 | | | 2 | 复胜正 ...

Market Performance - In the first half of 2025, the A-share market showed strong resilience amid a complex domestic and international environment, with the Shanghai Composite Index rising by 2.75% and the North Stock 50 Index leading with a remarkable increase of 39.45% [1] - The total trading volume in the A-share market reached 162.68 trillion yuan, significantly higher than the 101 trillion yuan recorded in the same period of 2024, indicating a rapid increase in market activity [1] Private Equity Fund Performance - Among the 495 billion private equity products with reported performance, the average return for the first half of the year was 10.18%, with an excess return of 8.84% [2] - There was a notable divergence in performance among different strategies, with quantitative long strategies achieving an average return of 18.84%, while subjective long strategies only averaged 3.32% [1][2] Strategy Breakdown Quantitative Long Strategies - A total of 194 quantitative long products were reported, with the top performers identified based on excess returns [3] - The leading product was from Longqi Technology, with significant returns attributed to favorable market conditions and a strong belief in the potential for excess returns in the Chinese market [7][8] Subjective Long Strategies - There were 165 subjective long products, with the average return being only 3.32%, highlighting a stark contrast with quantitative strategies [4][11] - The top-performing product in this category focused on medical innovation, benefiting from strong market trends in the healthcare sector [11] Market Neutral Strategies - The average return for 35 market-neutral products was reported at 6.62%, with notable performers including Mingcong Investment and Weiguan Asset [12][14] Multi-Asset Strategies - The average return for 46 multi-asset strategies was 6.45%, with several products achieving significant returns [15][17] Futures and Derivatives Strategies - The average return for 25 futures and derivatives products was 3.82%, with the top product from Xinhong Tianhe showing strong performance [19][22]

Core Viewpoint - The A-share market demonstrated strong resilience in the first half of 2025, with a "volatile upward and structurally differentiated" trend, as evidenced by the performance of various indices and a significant increase in trading volume [2] Market Performance - The Shanghai Composite Index rose by 2.75%, the Shenzhen Component Index increased by 0.48%, and the ChiNext Index gained 0.53%. The North Stock 50 Index, representing small-cap stocks, saw the highest increase of 39.45% [2] - Total trading volume in the A-share market reached 162.68 trillion yuan, significantly higher than the 101 trillion yuan recorded in the same period of 2024, indicating a rapid increase in market activity [2] Private Equity Fund Performance - In the first half of 2025, 495 products from billion-yuan private equity firms reported performance, with an average return of 10.18% and an excess return of 8.84% [2][3] - There was a notable divergence in performance among different strategies, with quantitative long strategies achieving an average return of 18.84%, while subjective long strategies only averaged 3.32% [2][3] Strategy Breakdown Quantitative Long Strategies - A total of 194 quantitative long products were analyzed, with the top performers based on excess returns [4] - The top 10 quantitative long products included firms such as Longqi Technology and Stable Investment, with Longqi Technology's product leading the list [5][8] Subjective Long Strategies - There were 165 subjective long products, with an average return of 3.32%, indicating a significant performance gap compared to quantitative strategies [8] - The top performers in this category included Harmony One Asset and Evolutionary Asset, with a focus on sectors like medical innovation [12][9] Market Neutral Strategies - 35 market-neutral products were evaluated, with the top 10 showing an average return of ***% [13] - Notable firms in this category included Mingyuan Investment and Micro博易 [16] Multi-Asset Strategies - 46 multi-asset products were reviewed, achieving an average return of 6.45% [17] - The leading product in this category was from Blackwing Asset, which demonstrated strong performance [19] Futures and Derivatives Strategies - 25 products in the futures and derivatives category were analyzed, with an average return of 3.82% [20] - The top product was from Xinhong Tianhe, which achieved significant excess returns [23]